MYND Life Sciences Inc.
MYND
CNSX
| 07/31/2024 | 04/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 14.76% | 35.74% | |||
| Gross Profit | -14.76% | -35.74% | |||
| SG&A Expenses | 79.67% | 11.51% | |||
| Depreciation & Amortization | -80.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 53.13% | -34.19% | |||
| Operating Income | -53.13% | 34.19% | |||
| Income Before Tax | -44.80% | 30.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -44.80% | 30.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -44.80% | 30.71% | |||
| EBIT | -53.13% | 34.19% | |||
| EBITDA | -53.44% | 34.22% | |||
| EPS Basic | -46.34% | 30.51% | |||
| Normalized Basic EPS | -42.31% | 29.73% | |||
| EPS Diluted | -46.34% | 30.51% | |||
| Normalized Diluted EPS | -42.31% | 29.73% | |||
| Average Basic Shares Outstanding | 0.00% | -1.64% | |||
| Average Diluted Shares Outstanding | 0.00% | -1.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||